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Abstract
Background: There is no consensus regarding resection of the primary tumour with few or absent symptoms in
patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the
primary tumour is to prevent complications of the primary tumour in later stages of the disease. We here propose
a randomized trial in order to demonstrate that resection of the primary tumour improves overall survival.
Methods/design: The CAIRO4 study is a multicentre, randomized, phase III study of the Dutch Colorectal Cancer
Group (DCCG). Patients with synchronous unresectable metastases of CRC and few or absent symptoms of the
primary tumour are randomized 1:1 between systemic therapy only, and resection of the primary tumour followed
by systemic therapy. Systemic therapy will consist of fluoropyrimidine-based chemotherapy in combination with
bevacizumab. The primary objective of this study is to determine the clinical benefit in terms of overall survival of
initial resection of the primary tumour. Secondary endpoints include progression free survival, surgical morbidity,
quality of life and the number of patients requiring resection of the primary tumour in the control arm.
Discussion: The CAIRO4 study is a multicentre, randomized, phase III study that will assess the benefit of resection
of the primary tumour in patients with synchronous metastatic CRC.
Trial registration: The CAIRO4 study is registered at clinicaltrials.gov (NCT01606098)
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Background
Colorectal cancer (CRC) is the third most common type
of cancer in the Netherlands, with an incidence of more
than 13,000 new cases in 2011 [1]. Due to the improve-
ment in living standard and the aging of the population,
the incidence of CRC is increasing. Approximately 20% of
patients with CRC present with synchronous metastases
(stage IV disease, according to TNM-classification) [2]. Al-
though curative surgery, with resection of both the primary
tumour and all metastases, is an option in some patients,
the majority of patients with stage IV disease end up in a
palliative setting.
Median survival in patients with advanced CRC with-
out any form of treatment is estimated at 8 months [3].
Palliative systemic treatment, consisting of cytotoxic
chemotherapy and targeted therapy, can lead to a signifi-
cant benefit in overall survival [4]. Standard of care in
the Netherlands in first-line treatment consists of fluoro
pyrimidine-based chemotherapy in combination with
bevacizumab [5].
To prevent complications from the primary tumour,
such as obstruction or bleeding, or to reduce symptoms,
resection of the primary tumour is often considered in this
patient group. Retrospective data show that approximately
50% of all patients with stage IV disease undergo resection
of the primary tumour [2,6]. The 30-day mortality rates
after surgery of the primary tumour for patients with stage
IV disease range between 1.3-11.7%, which is higher than
reported for elective surgery in stage I-III patients [7].
However, these rates usually reflect both symptomatic and
asymptomatic patients with a variety in age and comor-
bidity. Limited postoperative survival is furthermore asso-
ciated with an extensive hepatic tumour load, pT4
tumours, lymphatic spread and R1-2 resection [8].
The indication of palliative resection prior to initiation
of systemic treatment in patients with a symptomatic
primary tumour is obvious. However, in patients with
few or absent symptoms the indication for prophylactic
resection is under debate, and its effect on survival and
quality of life is still uncertain [9]. Currently, there are
no data from prospective randomized trials to assess the
value of resection of the primary tumour in stage IV
patients with mild or absent symptoms of their primary
tumour. Retrospective analysis does not provide definitive
answers, since usually no reliable information is provided
on the presence of symptoms at diagnosis or the indication
to perform or to refrain from resection of the primary
tumour. Most randomized studies in metastatic CRC do
not even report whether or not a resection of the primary
tumour has been performed [10].
Treatment in patients with unresectable metastatic CRC
should be based on two objectives: first, to improve or
maintain the quality of life, and, secondly, to prolong the
survival. In patients with few or absent symptoms of the
primary tumour, arguments both in favour and against ini-
tial resection have risen.
The main argument against resection of the tumour is
that survival benefit of initial resection of the primary
tumour has not yet been investigated in a prospective
randomized trial. Therefore, surgery-related morbidity
and mortality should be avoided [11-13]. Furthermore,
there is some evidence from preclinical and clinical data
showing that resection of the primary tumour may have
a stimulating effect on the growth of distant metastases
[14]. However, these data are mainly derived from
in vitro and animal models and it remains unknown if
and how they influence overall survival and quality of
life. Also, it is argued that systemic treatment can safely
be administered without prior resection of the primary
tumour [15]. Thus, life-prolonging systemic treatment
would only be postponed when it is decided to perform a
surgical intervention first [15-17]. Additionally, Poultsides
et al. demonstrate that most patients with synchronous
stage IV CRC who receive upfront systemic therapy
never require palliative surgery [15]. However, the me-
dian overall survival time in this study was only
13 months, whereas median overall survival times of
20–24 months have consistently been reported in the
general population of metastatic CRC patients. Lastly,
in 70% of patients who received systemic treatment
prior to resection of the primary tumour major histo-
logical tumour regression was observed, suggesting that
initial chemotherapy can control the primary tumour in
the majority of patients [18].
The main argument in favour of resection is that it will
prevent possible complications of the primary tumour,
such as bleeding, obstruction or perforation [19-21]. Pa-
tients who receive initial systemic therapy without prior
resection of the primary tumour are more likely to develop
complications of the primary tumour [22]. Furthermore,
surgery can lead to more accurate staging of disease, as ex-
trahepatic metastases, particularly in the peritoneal cavity,
may be better identified by visual exploration.
Retrospective analysis of two large randomized trials in
patients with advanced CRC demonstrated that survival of
patients with synchronous advanced CRC was significantly
higher in patients who underwent resection of the primary
tumour prior to study treatment, compared to patients
with the primary tumour in situ (20.7 vs. 13.4 months,
respectively) [23]. Symptoms which might be related to
the primary tumour, such as nausea, vomiting and ileus
did occur more often in the non-resection group. How-
ever, selection bias cannot be excluded, as the decision
whether or not a patient would undergo resection was
made prior to study entry. Therefore no data are available
on patient characteristics that might have influenced this
decision, such as resectability and symptomatology of the
primary tumour and condition of the patient.
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In summary, the available literature does not provide an
outright support for either of the two strategies, although
most support seems to exist for surgery of the primary
first (Table 1). We therefore propose a prospective trial
that will help provide an answer to the question which
strategy is to be preferred.
Methods/design
Hypothesis
Although literature does not provide an outright support
for either of the two strategies, most retrospective data
seem to favour surgery of the primary tumour followed by
systemic therapy over systemic therapy alone. Obviously,
in patients with few or absent symptoms of their primary
tumour, surgery can only be justified if a clinical benefit is
shown. Therefore, we hypothesize that surgery of the pri-
mary tumour improves overall survival in patients with
few or absent symptoms as evaluated by the treating phys-
ician and incurable stage IV CRC.
Study design
The CAIRO4 trial is an international, multicentre, ran-
domized, phase III study. Patients with synchronous unre-
sectable metastatic colorectal cancer with few or absent
symptoms of their primary tumour are randomized 1:1
between systemic treatment without resection of the pri-
mary tumour, and resection of the primary tumour
followed by systemic treatment. Treatment according to
protocol must be initiated within four weeks after
randomization. The study will be conducted within the
network of the Dutch Colorectal Cancer Group (DCCG)
and the Danish Colorectal Cancer Group. At least 55
Dutch hospitals and 5 Danish hospitals will participate in
this study, including 8 university medical centres.
Study population
All patients who are newly diagnosed with synchronous
metastatic CRC are eligible for participation in this trial
when they meet the following inclusion criteria: histo-
logically proven CRC (i.e. via colonoscopy and/or any
other method) with a resectable primary tumour in situ
and unresectable distant metastases without an indication
for neo-adjuvant (chemo)radiation, with few or absent
symptoms of the primary tumour, without prior systemic
treatment for advanced disease, with age ≥ 18 years and a
WHO performance status of 0, 1 or 2 [29]. Laboratory
serum values obtained ≤ four weeks prior to randomization
must show an adequate bone marrow function (Hb ≥
6.0 mmol/L, absolute neutrophil count ≥ 1.5°109/L, plate-
lets ≥ 100° 109/L), renal function (creatinine ≤ 1.5x upper
limit of normal (ULN) and creatinine clearing ≥ 30 ml/min
using the Cockcroft formula) and liver function (bilirubin ≤
2× ULN, transaminases ≤ 3× ULN in patients without hep-
atic metastases or ≤ 5x ULN in patients with presence of
liver metastases). Patients must have undergone a com-
puted tomography (CT) scan in the four weeks prior to
randomization. Adequate follow-up must be expected and
a written informed consent must be obtained before enrol-
ment in the study.
The following definition of few or absent symptoms is
used: patients without signs or symptoms related to the
primary tumour that require immediate intervention (i.e.
surgery, stenting, systemic therapy or radiotherapy). The
necessity of immediate intervention is left to the discretion
of the treating physician. Whether or not metastases are
resectable will be decided by the local multidisciplinary
tumour board.
Exclusion criteria are: pregnancy, lactation, unresectable
primary tumour, any condition preventing the safety or
feasibility of resection of the primary tumour, second pri-
mary malignancy ≤ 5 years prior to randomization with
Table 1 Data on resection versus non-resection of the primary tumour in metastatic CRC patients
Study Years of study Number of patients Median survival time (in months) p-value
Resection Non-resection Resection Non-resection
Liu [20] 1986-1991 57 5 11 2 n.a.
Ruo [24] 1996-1999 127 103 16 9 <0.001
Kaufman [25] 1998-2003 115 69 22 3 <0.0001
Scoggins [13] 1985-1997 66 23 14.5 16.6 0.59
Tebbutt [26] 1990-1999 280 82 14 8.2 0.08
Michel [27] 1996-1999 31 23 21 14 0.718
Benoist [16] 1997-2002 32 27 23 22 n.a.
Evans [28] 1999-2006 45 57 11 2 < 0.0001
Poultsides [15] 2000-2006 - 178 - 13
Venderbosch [23] 2003-2004 258 141 16.7 11.4 < 0.0001
2005-2006 289 159 20.7 13.4 <0.0001
n.a. = not applicable.
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the exception of basal cell carcinoma of the skin or
adequately treated in situ carcinoma of any organ, any
medical condition that prevents the safe administration of
systemic treatment, previous intolerance of fluoropyrimi-
dines, known dihydropyrimidine dehydrogenase deficiency,
possibility of radical resection of all metastatic disease,
uncontrolled hypertension (values ≥ 150/100 mmHg), use
of > 3 antihypertensive drugs, significant cardiovascular
disease < 1 year prior to randomization, chronic active
infection and concurrent treatment with any other anti-
cancer therapy as described per protocol. There are no ex-
clusion criteria considering the side of metastatic disease.
Because of the higher complexity of local treatment in
locally advanced rectal cancer, with patients often requiring
neoadjuvant (chemo)radiation therapy and higher risk of
morbidity and longer postoperative reconvalescence, these
patients are excluded from the study. Patients with rectal
cancer that do not require radiation therapy (i.e. rectal can-
cer with clinical staged T1-3 N0, extramural invasion ≤ 5
millimetres, distance to the mesorectal fascia > 1 millimetre
[5]), but otherwise do meet the inclusion criteria can
participate in the CAIRO4 study.
All patients who do not meet our inclusion criteria
and/or refuse participation to the trial, will be asked for
their consent for registration in a prospective database.
Interventions
Experimental arm: surgical resection prior to systemic
treatment
Patients will undergo surgical resection of the primary
tumour within four weeks of randomization, followed by
systemic therapy as described for the control arm. Surgical
resection of the tumour should be intended as R0 resec-
tion, and may be performed by laparoscopy or open sur-
gery, depending on the preference of the surgeon. If a
complete resection of the primary tumour cannot be per-
formed according to the operating team, a diverting stoma
or entero-enterostomy is strongly advised in order to pre-
vent complications of obstruction during follow-up. After
surgical resection, patients should commence palliative sys-
temic treatment as described for the control group when
they have sufficiently recovered, but not earlier than
4 weeks after surgery.
Control arm: systemic treatment
Patients will receive first-line fluoropyrimidine-based
chemotherapy with bevacizumab within four weeks of
randomization. The exact chemotherapy schedule is to
the discretion of the local investigator. Surgery of the pri-
mary tumour will only be performed when indicated by
local signs or symptoms, such as obstruction or bleeding.
Alternatively, if other palliative treatment options, such as
endoscopic stenting or radiotherapy, are considered more
suitable, either due to the nature of the symptoms or the
general condition of the patient, they may be used.
Duration of treatment and follow-up
The systemic therapy will be continued until progression
of disease or unacceptable toxicity, followed by salvage
therapy at the discretion of the local investigator. In case
of drug-related toxicity, this drug should be discontinued,
while, if possible, the other drugs should be continued. If a
treatment-free interval is considered to be in the best
interest of the patients, this is allowed.
Patients will be evaluated with CT scans and a clinical
encounter every 9–10 weeks for response, or in between
when progression is suspected. After permanent discon-
tinuation of therapy, patients will be followed every
3 months until progression or death.
If, at any time, the physicians involved in the treatment
believe an intervention with curative intent is possible, this
should be performed in any patient on the study. After
radical resection systemic therapy will only be continued
when advised by a multidisciplinary board of the local
treatment centre. Patients will remain on-study and will
be included in the analysis.
Study objectives
The primary objective of this trial is to determine the
clinical benefit in terms of overall survival of resection
of the primary tumour with few or absent symptoms in
patients with synchronous unresectable metastases of
CRC (intention-to-treat population).
Secondary objectives include progression free survival,
grade III and IV chemotherapy related toxicity, 30-day and
90-day surgery-related morbidity and mortality, quality of
life, number of patients who undergo secondary surgery of
initially unresectable metastases, number of patients who
never receive systemic therapy in the intervention arm,
interval between randomization and initiation of systemic
treatment, and overall survival in patients in whom treat-
ment according to protocol was initiated. In the control
arm we will also determine the percentage of patients re-
quiring resection of the primary tumour and the percent-
age of patients who require stenting or radiotherapy for
symptom palliation. Furthermore a cost-benefit analysis
will be performed, as well as translational research on
prognostic markers.
Endpoints
The primary study endpoint is overall survival, and the
study is designed to demonstrate a difference in median
overall survival of six months between both arms. Six
months is believed to be the minimal difference to justify
a surgical procedure in advanced patients. Although it
seems a large difference between the two arms, it is in line
with most published data (Table 1).
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Study assessment
All eligible randomized patients will be included in the
analysis (intent-to-treat). Overall survival is estimated
from the date of randomization to death from any cause.
Progression free survival is defined as the time measured
from the day of randomization to the date of first docu-
mented progression, or death from any cause. All adverse
events, clinical and laboratory symptomatology will be
graded according to NCI common toxicity criteria, version
4.0 [30].
Response will be assessed according to the RECIST cri-
teria for evaluation of response [31]. A baseline measure-
ment should be performed within 4 weeks prior to the
start of treatment via CT scanning. A chest X-ray may be
used provided in case of lung metastases if the target
lesion is unidimensionally measurable and has a diameter
of > 2 cm. Ultrasound and serum carcinoembryotic anti-
gen (CEA) are not considered adequate parameters for
disease evaluation.
Quality of life will be measured using the EORTC-QLQ
C30 and CR38 questionnaires [32,33], with a baseline
measurement within 2 weeks prior to randomization and
every six months thereafter, until the end of the study
treatment.
Statistical considerations
Sample size
In the control group the expected median overall survival
is 13 months. In order to demonstrate a clinically relevant
increase of 6 months in the experimental group, a total of
218 deaths are required (80% power, significance level
0.05). With a recruitment rate of 12 patients per month,
an accrual period of 30 months and a follow-up period of
8 months, a total of 360 patients are required in order to
detect a difference in median overall survival of 13 versus
19 months with a power of 80%.
Randomization
Patients will be randomized centrally for systemic treatment
versus surgery of the primary tumour in a 1:1 allocation ra-
tio, stratifying for number of metastatic sites (1 versus
more), serum lactate dehydrogenase (LDH, normal versus
abnormal), WHO performance status (0 or 1 versus 2) and
institution.
Primary analysis
An interim analysis at a significance level of 0.001 will be
performed when one third of the events have occurred.
The primary analysis will be a stratified log rank test on
the overall survival at a significance level of 0.049. The
sample size of 360 (180 per group) is such that still 79.6%
power is retained when testing a level of 0.049. Patients
without recurrence and alive at the time of the analysis
will be included as censored data.
Secondary parameters will be compared between the
two arms using stratified log rank tests (time-to-event
endpoints), chi-square tests (disease and outcome charac-
teristics) and t-tests (e.g. quality of life). Regression ana-
lysis will be used for translational research questions.
Ethics
The study was approved by the Central Committee of
Human-related Research and by the local ethics commit-
tees of all participating centres. The CAIRO4 study is reg-
istered at clinicaltrial.gov (NCT01606098) [34]. Prior to
registration written informed consent will be obtained in
all patients, with a separate informed consent for the
collection of samples for translational research.
An independent data monitoring committee consisting
of three senior medical and surgical oncologists and a stat-
istician, who are not involved in the study, will review the
safety data on a regular basis and report their findings to
the principal investigator. The principal investigator will
report these findings to the ethics committee.
Discussion
Although recent publications suggest that resection of the
primary tumour in synchronous metastatic CRC patients
might not be necessary, this appears to be based on feasi-
bility and not on clinical outcome. The CAIRO4 trial is
designed to analyse the role of resection of the primary
tumour in unresectable metastatic CRC.
This trial has been designed to evaluate two accepted
treatment strategies. Therefore, there are no specific direc-
tives regarding type of surgery and/or chemotherapy regi-
men. To the discretion of the local investigator, the
following chemotherapy schedules are allowed: 5FU/LV,
capecitabine, CAPOX, FOLFOX, FOLFIRI or CAPIRI
[35-39]. In both study arms bevacizumab will be added to
a fluoropyrimidine containing regimen according to the
Dutch national guideline [5]. Bevacizumab is a targeted
therapy, as it inhibits tumour neoangiogenesis by blocking
VEGF. Tumour neoangiogenesis is a prerequisite for
tumour growth. VEGF and VEGF-receptors have been
implicated in this process, and have been associated with
poor prognosis. Bevacizumab is worldwide accepted for
use in first-line treatment of advanced CRC and its benefit
has been confirmed by compelling data [40].
Considering current developments, it might be expected
that there will be a decreasing percentage of patients pre-
senting with incurable synchronous metastatic CRC. The
last decades have seen major improvements in both surgi-
cal techniques as well as effectiveness of adjuvant therapy,
which has led to a remarkable increase in five-year
survival rates [41]. Although approximately 20-25% of
patients present with synchronous distant metastatic
disease, with the development of new surgical techniques,
such as liver resection, pulmonary metastasectomy and
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hyperthermic intraperitoneal chemotherapy, an increasing
number of patients are treated with curative intent [42].
In selected patients this could lead to five-year survival
rates as high as 35-60% [43].
On the other hand, only a slight increase in the propor-
tion of stage IV disease was observed in the Netherlands
in the last two decades [41,44]. This increase is probably
due to an earlier and more accurate detection of distant
metastases, because of more widely available and im-
proved imaging techniques, such as magnetic resonance
imaging (MRI), positron emission tomography (PET) and
CT scanning. Although in many cases metastases might
be better resectable when detected in an earlier stage, in
others detection of unresectable metastases (i.e. in bone
or distant lymph nodes) might lead to refraining from
treatment with curative intent.
It can be argued that the development of nationwide
screening programmes will lead to an earlier detection of
CRC, and thus to a decreasing number percentage of ad-
vanced CRC [45-48]. However, randomized trials show that
the specific proportion of patients with synchronous meta-
static disease at diagnosis did not differ between the con-
trol group and the group that was offered screening
[45-47]. Therefore, despite current developments in both
detection and treatment of CRC, the issue of the best treat-
ment strategy in patients who present with synchronous
metastatic disease will still be relevant for future patients.
As of August 2012, the trial accrual for the CAIRO4
study has started in the above mentioned centres. Taking
in account the time needed to implement this study in all
centers, we expect that in five year time the recruitment
will be completed. This trial will provide an answer to the
question if resection of the primary tumour with few or
absent symptoms in patients with synchronous metastatic
CRC offers a clinical benefit in terms of overall survival
and quality of life.
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